NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CGTX

Cognition Therapeutics Inc

Apr 04 • 12:09PM ET

0.3450

Dollar change -0.0410
Percentage change -10.62	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB LLY SAVA AVXL BIVI VRTX AZN ACAD PRTA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.86	Insider Own	18.96%	Shs Outstand	59.85M	Perf Week	-17.01%
Market Cap	21.38M	Forward P/E	-	EPS next Y	-0.95	Insider Trans	0.33%	Shs Float	50.22M	Perf Month	-20.01%
Income	-33.97M	PEG	-	EPS next Q	-0.12	Inst Own	8.23%	Short Float	2.82%	Perf Quarter	-52.29%
Sales	0.00M	P/S	-	EPS this Y	52.79%	Inst Trans	18.89%	Short Ratio	0.92	Perf Half Y	-23.50%
Book/sh	0.31	P/B	1.10	EPS next Y	-133.37%	ROA	-103.89%	Short Interest	1.42M	Perf Year	-82.49%
Cash/sh	0.40	P/C	0.85	EPS next 5Y	26.97%	ROE	-157.19%	52W Range	0.34 - 2.95	Perf YTD	-50.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.44%	ROI	-177.93%	52W High	-88.31%	Beta	1.00
Dividend TTM	-	Quick Ratio	2.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	1.47%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	2.65	EPS Y/Y TTM	-0.38%	Oper. Margin	-	RSI (14)	31.52	Volatility	9.43% 9.08%
Employees	28	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	6.83
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	36.14%	Payout	-	Rel Volume	1.09	Prev Close	0.39
Sales Surprise	-	EPS Surprise	-11.00%	Sales Q/Q	-	Earnings	Mar 20 BMO	Avg Volume	1.54M	Price	0.34
SMA20	-19.19%	SMA50	-34.33%	SMA200	-53.70%	Trades		Volume	736,056	Change	-10.62%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-24	Upgrade	B. Riley Securities	Neutral → Buy	$1 → $1.50
Jul-30-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-03-21	Initiated	Oppenheimer	Outperform	$22
Nov-03-21	Initiated	B. Riley Securities	Buy	$27

Apr-01-25 07:30AM	Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes (GlobeNewswire) -6.82%
Mar-25-25 07:30AM	Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 (GlobeNewswire) -6.23%
Mar-21-25 03:01AM	Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ... (GuruFocus.com) +6.61%
12:18AM	Q4 2024 Cognition Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 01:15PM	Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call Transcript (SeekingAlpha) -5.18%
07:00AM	Loading…
07:00AM	Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) +7.81%
Mar-13-25 04:05PM	Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results (GlobeNewswire)
Mar-12-25 04:05PM	Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing (GlobeNewswire)
01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-10-25 07:30AM	Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference (GlobeNewswire)
Feb-27-25 07:30AM	Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD (GlobeNewswire) -7.41%
Feb-26-25 07:00AM	Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy (GlobeNewswire)
Feb-25-25 07:30AM	Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit (GlobeNewswire) -7.87%
Feb-20-25 07:30AM	Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer's Candidate, Zervimesine (CT1812) (GlobeNewswire)
07:30AM	Loading…
Jan-30-25 07:30AM	Cognition's Positive Phase 2 'SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC (GlobeNewswire)
Jan-08-25 04:14PM	Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences (GlobeNewswire)
Dec-20-24 07:21AM	B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data (TipRanks)
Dec-19-24 07:31AM	Cognition Therapeutics announces results in Phase 2 study of CT1812 (TipRanks) +9.31%
Dec-18-24 07:22AM	Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies (GlobeNewswire) +27.50%
Nov-28-24 09:55AM	Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-26-24 07:40AM	Cognition Therapeutics provided an update on Phase 2 SHINE study analysis (TipRanks)
07:30AM	Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies (GlobeNewswire)
Nov-25-24 07:30AM	Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population (GlobeNewswire)
Nov-15-24 08:35AM	Life Sciences Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -9.85%
Nov-13-24 07:30AM	Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update (GlobeNewswire) -10.24%
Nov-12-24 08:35AM	Life Sciences Investor Forum Agenda Announced for November 14th (GlobeNewswire) +18.00%
07:30AM	Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum (GlobeNewswire)
Oct-31-24 04:15PM	Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD (GlobeNewswire) -11.09%
Oct-29-24 12:55PM	Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD (GlobeNewswire) +5.15%
07:30AM	Loading…
Oct-23-24 07:30AM	Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD (GlobeNewswire) +24.35%
Oct-22-24 07:30AM	Cognition Therapeutics Releases New Episode of Conversations Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) (GlobeNewswire)
Oct-09-24 05:37PM	Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ... (GuruFocus.com)
Oct-02-24 07:30AM	Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference (GlobeNewswire)
Oct-01-24 07:30AM	Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia (GlobeNewswire) -6.06%
Sep-03-24 07:30AM	Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences (GlobeNewswire) -10.88%
Aug-22-24 07:31AM	Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Aug-08-24 07:00AM	Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update (GlobeNewswire)
Aug-05-24 07:30AM	Cognition Therapeutics to Report Second Quarter 2024 Financial Results (GlobeNewswire) -9.95%
Jul-30-24 06:32AM	Cognition Therapeutics stock dips 43% following trial results for Alzheimers candidate (Clinical Trials Arena) -17.29%
Jul-29-24 11:58AM	Tivic Health Systems (TIVC) Stock Pops Another 39% (InvestorPlace) -43.88%
07:00AM	Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients (GlobeNewswire)
Jul-26-24 04:11PM	Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024 (GlobeNewswire) +12.86%
Jul-02-24 07:30AM	Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC (GlobeNewswire) +8.98%
May-21-24 07:30AM	Cognition Therapeutics Releases New Episode of Conversations Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease (GlobeNewswire) +8.10%
May-07-24 01:53PM	CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update (GlobeNewswire)
Apr-29-24 07:30AM	Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies (GlobeNewswire)
Apr-22-24 07:30AM	Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease (GlobeNewswire)
Apr-02-24 07:30AM	Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-01-24 07:30AM	Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024 (GlobeNewswire)
Mar-27-24 09:31AM	Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call Transcript (Insider Monkey)
01:13AM	Q4 2023 Cognition Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-26-24 11:53AM	CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-15-24 07:30AM	Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Mar-14-24 04:05PM	Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock (GlobeNewswire)
Mar-11-24 08:16PM	Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock (GlobeNewswire) -6.60%
04:05PM	Cognition Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-06-24 07:30AM	Cognition Therapeutics Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies (GlobeNewswire)
Feb-26-24 07:30AM	Cognition Therapeutics to Present at the TD Cowen Health Care Conference (GlobeNewswire)
Feb-06-24 08:47AM	New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812 (GlobeNewswire)
Jan-04-24 07:30AM	Cognition Therapeutics CEO Issues Letter to Shareholders (GlobeNewswire)
Nov-16-23 07:30AM	Cognition Therapeutics Releases New Episode of Conversations Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens (GlobeNewswire)
Nov-15-23 07:30AM	Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's Diseases (GlobeNewswire)
Nov-07-23 07:30AM	Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Nov-03-23 06:00AM	Cognition Therapeutics Inc (CGTX) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-02-23 07:30AM	Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -6.42%
Oct-27-23 07:30AM	Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer's Disease at CTAD (GlobeNewswire)
Oct-24-23 04:30PM	Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTAD (GlobeNewswire)
Oct-16-23 07:30AM	Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications (GlobeNewswire) +8.93%
Sep-07-23 07:45AM	Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD (GlobeNewswire)
Aug-30-23 08:00AM	Cognition Therapeutics Announces Participation in Upcoming September Conferences (GlobeNewswire) +12.95%
Aug-09-23 09:09AM	Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? (Simply Wall St.)
Aug-08-23 09:52PM	Q2 2023 Cognition Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Aug-02-23 07:30AM	Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023 (GlobeNewswire)
Jul-11-23 07:30AM	Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD (GlobeNewswire)
Jul-05-23 07:30AM	Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimers Disease (GlobeNewswire) -8.47%
Jun-28-23 07:00AM	Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimers Disease (GlobeNewswire) -12.80%
Jun-27-23 07:17PM	Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023 (GlobeNewswire) -11.03%
Jun-20-23 07:30AM	Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimers Disease Approaches (GlobeNewswire) -5.33%
Jun-02-23 07:30AM	Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences (GlobeNewswire) +12.05%
May-23-23 09:40AM	Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year? (Zacks)
07:30AM	Cognition Therapeutics Latest Episode of Conversations Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC (GlobeNewswire)
May-18-23 03:53PM	A Dose of Hope: Cognition's CT1812 Proves Its Mettle in Alzheimer's A Oligomer Displacement (Benzinga) +14.94%
07:30AM	Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces A Oligomers from Binding to Neuronal Synapses in Alzheimers Disease (GlobeNewswire)
May-04-23 04:05PM	Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -6.59%
May-01-23 07:30AM	Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer (GlobeNewswire) -7.30%
Apr-19-23 07:30AM	Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023 (GlobeNewswire)
Apr-12-23 07:30AM	Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases (GlobeNewswire)
Mar-28-23 07:30AM	Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimers Disease Processes (GlobeNewswire)
Mar-27-23 08:00AM	Cognition Therapeutics Announces New Episode of Conversations Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies (GlobeNewswire) +7.73%
07:12AM	Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-23-23 11:03PM	Q4 2022 Cognition Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +6.01%
07:30AM	Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-21-23 08:00AM	Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimers Disease at AD/PD 2023 (GlobeNewswire)
Mar-16-23 12:18PM	UPDATE Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results (GlobeNewswire) +13.33%
07:30AM	Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Mar-15-23 07:30AM	Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD (GlobeNewswire)

Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer's disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ricciardi Lisa	CEO & President	Jan 31 '25	Buy	0.77	38,851	30,001	38,851	Feb 04 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGTX

Cognition Therapeutics Inc

Upgrade your FINVIZ experience